Pancreaticobiliary Neoplasm

cancer family

Identifier: CI-CAN-00000309
Entity page: /cancer/pancreaticobiliary-neoplasm ↗
Edges: 5,534

Neighbours: 15 genes21 drugs10 trials
Drawn: 46 of 46 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Pancreaticobiliary Neoplasm approved for …APPROVED_FORderived15 of 19show all (up to 200)
← approved for	Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · Pancreatic Adenocarcinoma	—	approved	Pancreatic Adenocarcinoma	1	Regulatory	openfda	graph →
← approved for

Pancreaticobiliary Neoplasm altered in cohorts of …ALTERED_INderived15 of 241show all (up to 200)
← altered in cohorts of	HTR6 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KLHDC7A 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MRTO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TAS1R2 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TMCO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AADACL3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AADACL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTL8 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AHDC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AKR7A3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ALDH4A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ALPL 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ARHGEF10L 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATP13A2 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →

Pancreaticobiliary Neoplasm altered in cohorts of …ALTERED_INderived15 of 241show all (up to 200)

← altered in cohorts of

HTR6

42 / 51 cases (82 %) · ssm · TCGA-CHOL

—

Cholangiocarcinoma

Observed

Pancreaticobiliary Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 270show all (up to 200)
→ investigated in trials for	Gemcitabinesmall molecule 704 trials (141 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	704	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 256 trials (91 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	256	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 178 trials (47 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	178	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 159 trials (40 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	159	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 155 trials (29 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	155	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 134 trials (44 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	134	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 105 trials (37 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	105	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 101 trials (33 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	101	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 95 trials (38 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	95	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 71 trials (14 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	71	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 57 trials (29 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 57 trials (20 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 50 trials (15 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	50	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 42 trials (12 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 38 trials (11 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	38	Observed	clinicaltrials	graph →

Pancreaticobiliary Neoplasm studied in …STUDIED_INderived10 of 5,004show all (up to 200)
→ studied in	NCT01824875Phase 2 · completed Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors · condition mapped ALIAS · 5,004 trials mapped (1,535 active)	—	—	Pancreatic Glucagonoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 5,004 trials mapped (1,535 active)	—	—	Exocrine Pancreas Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02598349Phase 2 · recruiting Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas · condition mapped CURATED_EXACT · 5,004 trials mapped (1,535 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04175912Phase 2 · active not recruiting Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 5,004 trials mapped (1,535 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04396821Phase 1/Phase 2 · active not recruiting A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors · condition mapped CURATED_EXACT · 5,004 trials mapped (1,535 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04548752Phase 2 · active not recruiting Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations · condition mapped CURATED_BROADER · 5,004 trials mapped (1,535 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04605913Phase 1/Phase 2 · active not recruiting Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC · condition mapped ALIAS · 5,004 trials mapped (1,535 active)	—	—	Pancreatic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05877599Phase 1 · recruiting A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 5,004 trials mapped (1,535 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05927142Phase 1/Phase 2 · active not recruiting Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy · condition mapped CURATED_BROADER · 5,004 trials mapped (1,535 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06046794NA · recruiting Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · condition mapped ALIAS · 5,004 trials mapped (1,535 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains